Financings Roundup
Ariad Pads Cash with $300M For Iclusig Launch, Clinic Work
A month after the earlier-than-expected approval of Iclusig (ponatinib) in chronic myelogenous leukemia (CML), Ariad Pharmaceuticals Inc. is taking advantage of the current public markets to more than double its cash balance.